Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)
The primary efficacy objectives of this study are to demonstrate that sensitivity and specificity of gadobutrol-enhanced CMRI exceed pre-specified minimum performance thresholds (MPT) of 60 and 55%, r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer AB, Bayer Health Care, Bayer Schering Pharma
Update Il y a 4 ans
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children
The primary objective is to evaluate pharmacokinetic parameters of Gadovist 1.0 in plasma at the standard dose of 0.1 mmol/kg body weight in children of different age according to ICH E 11. To determ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment versus 300 mg Aspirin® N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition
To demonstrate superiority of 500 mg and 250 mg Aspirin® i.v. (BAY 81-8781) treatment over oral treatment with 300 mg Aspirin® N tablets to inhibit thromboxane A2-release (measured as stable metaboli...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
Bayer 12913 : Essai de phase 2 en escalade de dose évaluant l’efficacité et la tolérance d’une 1ère ligne de traitement par sorafénib chez des patients ayant un carcinome rénal. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase II, multi-centre, open-label study to assess the efficacy, safety, tolerability and pharmacokinetics of intrapatient dose escalation of sorafenib as first line treatment for metastatic renal c...
Country
France
organs
Rein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 80876395) in a 21-day regimen as compared to a monophasic contraceptive containing ethinyestradiol and levonogestrel (0.33 mg/0.15 mg) in a 21-day regimen on hemostatic parameters in 30 women aged 18-35 years over 3 treatment cycles in each period
To investigate the impact of the transdermal contraceptive patch in a 21-day regimen on hemostasis parameters in comparison to a combined oral contracetive in a 21-day regimen.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Evaluation of a Treat and Extend regimen of intravitreal aflibercept for macular edema secondary to CRVO
To determine the efficacy and durability (treatment interval) of 2 mg IVT aflibercept in a T&E regimen over a treatment period of 76 weeks using protocol defined visual and anatomic criteria in subjec...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose- Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients with Essential Hypertension
To determine the dose-response of the various combinations of nifedipine GITS (gastrointestinal therapeutic system) and candesartan as compared to monotherapy and placebo based on the blood pressure (...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen compared to ethinylestradiol / desogestrel (0.02 mg/0.15 mg) oral contraception in a 21/7 regimen on hormone withdrawal associated symptoms in otherwise healthy women after 4 cycles of treatment
To show superiority of 24/4 OC to 21/7 OC with regard to changes in frequency and intensity of hormone withdrawal associated symptoms on cycle days 22 – 28 from baseline to cycle 4 in approximately 55...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compared to postmortem histopathology
To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological verification of the presence or absence of cerebr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study
to evaluate accidental evidence (casuistic findings) in more detail and to show efficacy of vardenafil superior over placebo in the treatment of chronic tinnitus
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next